Latest Breaking News On - Medicenna therapeutics - Page 14 : comparemela.com

Medicenna Therapeutics (MDNA) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Medicenna Therapeutics (NASDAQ:MDNA – Free Report) in a research note issued to investors on Monday morning, Benzinga reports. They currently have a $2.50 price target on the stock. HC Wainwright also issued estimates for Medicenna Therapeutics’ Q2 2024 earnings at ($0.05) EPS, Q3 2024 earnings at […]

Renaissance technologiesMillennium managementMedicenna therapeutics corpMedicenna therapeutics company profileLetko brosseau associates incSigma planning corpWorth venture partnersMedicenna therapeuticsFree reportGet free reportPlanning corpVenture partnersTherapeutics corpMedicenna therapeutics dailyNasdaq mdnaReiterated rating

Medicenna Therapeutics to Provide Clinical Update from Phase 1/2 ABILITY Study on August 9, 2023

TORONTO and HOUSTON, Aug. 04, 2023 (GLOBE NEWSWIRE) Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical-stage…

New yorkUnited statesKevin carmichaelGabriel friedmanSuperkine immunotherapiesJake edmistonMedicenna therapeutics corpNational postMedicenna therapeuticsProvide clinical updateVictoria wellsFinancial timesFinancial postNew york timesOrphan drug

Medicenna Therapeutics (TSE:MDNA) Shares Down 3 4%

Medicenna Therapeutics (TSE:MDNA) Shares Down 3 4%
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Medicenna therapeutics company profileMedicenna therapeutics corpMedicenna therapeuticsGet free reportTherapeutics stock downTherapeutics corpMedicenna therapeutics daily

Q2 2024 Earnings Estimate for Medicenna Therapeutics Corp (NASDAQ:MDNA) Issued By HC Wainwright

Q2 2024 Earnings Estimate for Medicenna Therapeutics Corp (NASDAQ:MDNA) Issued By HC Wainwright
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Letko brosseau associates incWorth venture partnersSigma planning corpMillennium managementMedicenna therapeutics corpRenaissance technologiesMedicenna therapeuticsFree reportMedicenna therapeuticGet free reportPlanning corpVenture partnersTherapeutics corpMedicenna therapeutics daily

Medicenna Therapeutics (MDNA) Granted US Patent for the Use of Interleukin-2 Superkine Fusion Proteins in Oncology

Medicenna Therapeutics (MDNA) Granted US Patent for the Use of Interleukin-2 Superkine Fusion Proteins in Oncology
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSuperkine immunotherapiesElizabeth williamsTony russoMedicenna therapeutics corpCompany superkineMedicenna therapeuticsUses thereofBifunctional superkineFahar merchantOrphan drugLooking statementsthisAnnual information formAnnual reportChief financial officerRusso partners